Antinociceptive interaction of (±)-CPP and propentofylline in monoarthritic rats

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Morales, Francisco ^a   Constandil, Luis ^a   Pelissier, Teresa ^b   Hernández, Alejandro ^a   Laurido, Claudio ^a  

^a UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXIPIPERAZIN 4) 1 PROPYL PHOSPHONIC ACID; ANTINOCICEPTIVE AGENT; GLUTAMATE RECEPTOR ANTAGONIST; PROPENTOFYLLINE; UNCLASSIFIED DRUG; 3-(2-CARBOXYPIPERAZIN-4-YL)PROPYL-1-PHOSPHONIC ACID; PIPERAZINE DERIVATIVE; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; LOW DRUG DOSE; MALE; MECHANICAL STIMULATION; MONARTHRITIS; NONHUMAN; RAT; ANIMAL; ARTHRITIS, EXPERIMENTAL; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; PAIN; PAIN MEASUREMENT; PATHOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; MALE; PAIN; PAIN MEASUREMENT; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; XANTHINES;

EID: 84865279940     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4030     Document Type: Article

References (55)

1. Paeile J, Bilbeny N. El dolor: de lo molecular a lo clínico. 2005, Santiago-Buenos Aires: Editorial Mediterráneo, 3.
2. Watkins L, Maier S. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985. 10.1038/nrd1251, 14654796.
3. Malenka RC, Nicoll RA. Long-term potentiation: a decade of progress?. Science 1999, 285:1870-1874. 10.1126/science.285.5435.1870, 10489359.
4. Sepulveda FJ, Bustos FJ, Inostroza E, Zúñiga FA, Neve RL, Montecino MA, Van Zundert B. Differential roles of NMDA receptor subtypes NR2A and NR2B in dendritic branch development and requirement of RasGRF1. J Neurophysiol 2010, 103:1758-1770. 10.1152/jn.00823.2009, 20107120.
5. Monyer H, Sprengel R, Schaefer, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992, 256:1217-1221. 10.1126/science.256.5060.1217, 1350383.
6. Pelissier T, Infante C, Constandil L, Espinosa J, De Lapeyra C, Hernandez A. Antinociceptive effect and interaction of uncompetitive and competitive NMDA receptor antagonists upon capsaicin and paw pressure testing in normal and monoarthritic rats. Pain 2008, 134:113-127. 10.1016/j.pain.2007.04.011, 17517475.
7. Ren K, Hylden JL, Williams GM, Ruda MA, Dubner R. The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain 1992, 50:331-344. 10.1016/0304-3959(92)90039-E, 1454389.
8. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ. Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res 1992, 598:271-278. 10.1016/0006-8993(92)90193-D, 1362520.
9. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ, Frenk H. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res 1993, 605:164-168. 10.1016/0006-8993(93)91368-3, 8385540.
10. Persson J, Axelsson G, Hallin RG, Gustafsson LL. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain 1995, 60:217-222. 10.1016/0304-3959(94)00139-6, 7784107.
11. Mathisen LC, Per Skjelbred P, Lasse AS, Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 1995, 61:215-220. 10.1016/0304-3959(94)00170-J, 7659431.
12. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Neurosci 2009, 10:23-36.
13. Haydon PG. Glia: listening and talking to the synapse. Nat Rev Neurosci 2001, 2:185-193. 10.1038/35058528, 11256079.
14. Sweitzer S, Colburn R, Rutkdwski M, DeLeo J. Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res 1999, 829:209-221. 10.1016/S0006-8993(99)01326-8, 10350552.
15. De Leo JA, Colburn RW. Proinflammatory cytokines in glial cells: their role in neuropathic pain. Cytoquines and Pain (Progress in Inflammation Research) 1999, 159-182. Basel: Birkhauser, Watkins LR, Maiser SF.
16. Garrison C, Dougherty P, Kajander K, Carlton S. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 1991, 565:1-7. 10.1016/0006-8993(91)91729-K, 1723019.
17. Watkins L, Maier S. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002, 82:981-1011.
18. Constandil L, Pelissier T, Soto-Moyano R, Mondaca M, Sáez H, Laurido C, Muñoz C, López N, Hernández A. Interleukin-1β increases spinal cord wind-up activity in normal but not in monoarthritic rats. Neurosci Lett 2003, 342:139-142. 10.1016/S0304-3940(03)00278-7, 12757884.
19. Inoue A, Ikoma K, Morioka N, Kumagai K, Hashimoto T, Hide I, Nakata Y. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J Neurochem 1999, 73:2206-2213.
20. Tawfik VL, Regan MR, Haenggeli C, LaCroix-Fralish ML, Nutile-McMenemy N, Perez N, Rothstein JD, DeLeo JA. Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transaction. Neuroscience 2008, 152:1086-1092. 10.1016/j.neuroscience.2008.01.065, 2423012, 18358622.
21. Schubeert P, Rudolphi K. Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alzheimer Dis Assoc Disord 1998, 12:S21-S28. 10.1097/00002093-199803001-00003, 9876939.
22. Platzer C, Fritsch E, Elsner T, Lehmann MH, Volk HD, Prosch S. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur J Immunol 1999, 29:3098-3104. 10.1002/(SICI)1521-4141(199910)29:10<3098::AID-IMMU3098>3.0.CO;2-H, 10540320.
23. Parkinson FE, Paterson ARP, Young JD, Cass CE. Inhibitory effects of propentofylline on [3H] adenosine influx. Biochem Pharmacol 1993, 46:891-896. 10.1016/0006-2952(93)90499-M, 8373440.
24. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998, 347:1-11. 10.1016/S0014-2999(97)01605-1, 9650842.
25. Tallarida RJ. Drug Synergism and Dose-Effect Data Analysis. 2000, New York: Chapman & Hall/CRC.
26. Jayo M, Cisneros J. Guía para el Cuidado y Uso de los Animales de Laboratorio. 1996, Washington, DC: National Academy Press.
27. Livingston A. Pain and analgesia in non-mammalian species. Proceedings of Do Animals Have Pain 1999, 159-165. Vienna: IASP Press, Thalhammer JG, Short CE.
28. Butler S, Godefroy F, Besson JM, Weil-Fugazza J. A limited arthritic model for chronic pain studies in the rat. Pain 1992, 48:73-81. 10.1016/0304-3959(92)90133-V, 1738577.
29. Mestre C, Pelissier T, Fialip J, Wilcox G, Eschalier A. A method for perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods 1994, 32:197-200. 10.1016/1056-8719(94)90087-6, 7881133.
30. Miranda HF, Prieto JC, Pinardi G. Spinal synergy between nonselective cyclooxygenase inhibitors and morphine antinociception in mice. Brain Res 2005, 1049:165-170. 10.1016/j.brainres.2005.04.068, 15936732.
31. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
32. Berenbaum MC. What is synergy?. Pharmacol Rev 1989, 41:93-141.
33. Tallarida R. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 2006, 319:1-7. 10.1124/jpet.106.104117, 16670349.
34. Mitchell CL. Statistical analysis of drug interactions. NIDA Res Monogr 1986, 68:41-64.
35. Whitehead KJ, Smith CGS, Delaney S-A, Curnow SJ, Salmon M, Hughes JP, Chessell IP. Dynamic regulation of spinal pro-inflammatory cytokine release in the rat in vivo following peripheral nerve injury. Brain Behav Immun 2010, 24:569-576. 10.1016/j.bbi.2009.12.007, 20035858.
36. Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert P. Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res 1998, 23:97-104.
37. Cho S, Kim Y, Cruz MO, Park EM, Chu CK, Song GY, Joh TH. Repression of proinflammatory cytokine and inducible nitric oxide synthase (NOS2) gene expression in activated microglia by N-acetyl-O-methyldopamine: protein kinase A-dependent mechanism. Glia 2001, 33:324-333. 10.1002/1098-1136(20010315)33:4<324::AID-GLIA1031>3.0.CO;2-M, 11246231.
38. Lashbrook JM, Ossipova MH, Hunterb JC, Raffacd RB, Tallaridad RJ, Porrecaa F. Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1 and COX2 inhibitors in nerve-injured rats. Pain 1999, 82:65-72. 10.1016/S0304-3959(99)00031-7, 10422661.
39. Constandil L, Goich M, Hernández A, Bourgeais L, Cazorla M, Hamon M, Villanueva L, Pelissier T. Cyclotraxin-B, a new TrkB antagonist, and glial blockade by propentofylline, equally prevent and reverse cold allodynia induced by BDNF or partial infraorbital nerve constriction in mice. J Pain 2012, 13:579-589. 10.1016/j.jpain.2012.03.008, 22560237.
40. Tarsa L, Bałkowiec-Iskra E, Kratochvil J, Jenkins VK, McLean A, Brown S, Smith JA, Baumgartner C, Balkowiec A. Tooth pulp inflammation increases BDNF expression in rodent trigeminal ganglion neurons. Neuroscience 2010, 167:1205-1215. 10.1016/j.neuroscience.2010.03.002, 2862813, 20223282.
41. Lin YT, Ro L-S, Wang H-L, Chen J-C. Up-regulation of dorsal root ganglia BDNF and trkB receptor in inflammatory pain: an in vivo and in vitro study. J Neuroinflammation 2011, 8:126. 10.1186/1742-2094-8-126, 3203068, 21958434.
42. Onda Y, Murata Y, Rydevik B, Larsson K, Kikuchi S, Olmarker K. Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. Spine 2004, 29:1857-1861. 10.1097/01.brs.0000137054.08788.b2, 15534405.
43. Pezet S, McMahon S. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006, 29:507-538. 10.1146/annurev.neuro.29.051605.112929, 16776595.
44. Coull JM, Beggs M, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter M, De Konink Y. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005, 438:1017-1021. 10.1038/nature04223, 16355225.
45. Tokumine J, Kakinohana O, Cizkova D, Smith DW, Marsala M. Changes in spinal GDNF, BDNF, and NT-3 expression after transient spinal cord ischemia in the rat. J Neurosci Res 2003, 74:552-561. 10.1002/jnr.10760, 14598299.
46. Merighi A, Salio C, Ghirri A, Lossi L, Ferrini F, Betelli C, Bardoni R. BDNF as a pain modulator. Progr Neurobiol 2008, 85:297-317.
47. Zhang W, Liu L-Y, Xu TL. Reduced potassium-chloride co-transporter expression in spinal cord dorsal horn neurons contributes to inflammatory pain hypersensitivity in rats. Neuroscience 2008, 152:502-510. 10.1016/j.neuroscience.2007.12.037, 18262726.
48. Raigorodsky G, Urca G. Involvement of N-methyl-D-aspartate receptors in nociception and motor control in the spinal cord of the mouse: behavioral, pharmacological and electrophysiological evidence. Neuroscience 1990, 36:601-610. 10.1016/0306-4522(90)90003-M, 1978259.
49. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991, 44:293-299. 10.1016/0304-3959(91)90100-C, 1828878.
50. Ma QP, Woolf CJ. Noxious stimuli induce an N-methyl-D-aspartate receptor-dependent hypersensitivity of the flexion withdrawal reflex to touch: implications for the treatment of mechanical allodynia. Pain 1995, 61:383-390. 10.1016/0304-3959(94)00195-K, 7478681.
51. Kristensen JD, Karlsten R, Gordh T, Berge OG. The NMDA antagonist 3-(2-carboxypiperazin-4-yl) propyl-1-phosphonic acid ((±)-CPP) has antinociceptive effect after intrathecal injection in the rat. Pain 1994, 56:59-67. 10.1016/0304-3959(94)90150-3, 8159442.
52. Goldstein FJ. Adjuncts to opioid therapy. J Am Osteopath Assoc 2002, 102:S15-S21.
53. Hameed H, Hameed M, Christo PJ. The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of analgesic drugs. Curr Pain Headache Rep 2010, 14:96-104. 10.1007/s11916-010-0093-y, 20425198.
54. Kalso E. Improving opioid effectiveness: from ideas to evidence. Eur J Pain 2005, 9:131-135. 10.1016/j.ejpain.2004.05.007, 15737801.
55. Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005, 13:188-193. 10.1007/s00520-004-0684-4, 15480820.